Release
Date: 1/1/2023
Expiration
Date: 1/1/2024
Activity Overview
Teprotumumab, a disease-modifying therapy, is currently the only drug approved by the FDA specifically for the thyriod eye disease (TED). Despite being available since 2020, there are no guidelines to optimize its use in clinical practice. To address this gap, an expert panel came to a consensus on teprotumumab treatment recommendations, includding when to initiate treatment, pretreatment considerations, monitoring throughout treatment, and strategies for mitigating and managing treatment-related adverse effects.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Manage patients with TED who are candidates for or are treated with an FDA-approved disease-modifying therapy
Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have recieved a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at
ketrea
@akhcme.com
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and International Healthcare Media, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
|
Name
|
Relationship
|
Commercial Interest
|
|
Christina T. Loguidice
|
N/A
|
Nothing to disclose
|
|
Dorothy Caputo, MA, BSN, RN, Senior Director of Continuing Education & Compliance
|
N/A
|
Nothing to disclose
|
|
Nuchele Bielarski, RN (planner/reviewer)
|
N/A
|
Nothing to disclose
|
|
AKH Inc. Staff and Planners
|
N/A
|
Nothing to disclose
|
|
International Healthcare Media, LLC Staff and Planners
|
N/A
|
Nothing to disclose
|
|
All of the relevant financial relationships listed for these individuals have been mitigated.
|
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.